Since YB-1 is known to be upregulated during prostate tumor progression, and found to promote AR expression10, qRT-PCR and Western blot analyses were used to show the significant decrease in mRNA and protein levels of AR, YB-1 and PSA upon androgen treatment (Fig. 2b–e). Here, AR is linked to prostate neoplasm.